UrologyNews.net

Urology Xagena

Xagena Mappa
Medical Meeting
Farmaexplorer.it
Dermabase.it

Search results for "Urothelial carcinoma"

About one half of all bladder neoplasms are non-invasive, and in those, the histologic grade is a crucial prognosticator. Few single-Center studies have assessed the recurrence, progression, and can ...


Typically in invasive papillary urothelial carcinoma both the overlying papillary and the invasive components are high grade. Researches have described a series of patients with invasive low-grade ...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the treatment of people with locally advanced or metastatic urothelial carcinoma ( mUC ...


The efficacy and safety of a combination of chemotherapeutic agent compared with single-agent chemotherapy in the second-line setting of advanced urothelial carcinoma ( UC ) are unclear. Researchers ...


Researchers have evaluated the association of ABO blood type with clinicopathologic outcomes and mortality among patients with urothelial carcinoma of the bladder treated with radical cystectomy. 2 ...


Preclinical urothelial carcinoma models suggest activity of Dasatinib ( Sprycel ), an oral Src-family kinase ( SFK ) inhibitor. Researchers have determined the feasibility and biologic activity of n ...


Body mass index ( BMI ) has been associated with worse outcomes in several solid malignancies. A study has evaluated the association between BMI and oncological outcomes in patients treated with radic ...


Intestinal metaplasia of the bladder is an uncommon glandular proliferation. Researchers have examined a large series of intestinal metaplasia for the clinicopathological features and discuss the sign ...


Although immune checkpoint inhibitors ( ICI ) have improved outcomes in some patients with Platinum-resistant metastatic urothelial carcinoma ( mUC ), many patients ( eg, patients with TCGA luminal 1 ...


Activation of FGFR signaling is involved in a variety of malignancies including advanced urothelial cancer. Rogaratinib is an oral pan-FGFR kinase inhibitor. Results from a phase I expansion co ...